SEC Declares Pfizer’ Registration Statement Effective For Acquisition Of Wyeth

Published: 18-Jun-2009

Transaction expected to close during the fourth quarter of 2009

Pfizer has announced that the US Securities and Exchange Commission (SEC) has declared effective Pfizer’ Registration Statement on Form S-4. The Form S-4 registers with the SEC Pfizer’s common stock to be issued in connection with the pending acquisition of Wyeth.

In addition, the form S-4 includes Wyeth’s Proxy Statement for its annual meeting of stockholders to be held on July 20, 2009, at which Wyeth’s stockholders will vote on the merger agreement with Pfizer.

Completion of this transaction remains subject to the following: expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the US, governmental and regulatory approvals, approval by the stockholders of Wyeth, and other usual and customary closing conditions. Subject to the satisfaction of the foregoing conditions, it is expected that the transaction will close at the end of the third quarter or during the fourth quarter of 2009.

Tell your friend about this article